205 related articles for article (PubMed ID: 37394589)
1. Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer.
Kim JY; Park S; Cho EY; Lee JE; Jung HH; Chae BJ; Kim SW; Nam SJ; Cho SY; Park YH; Ahn JS; Lee S; Im YH
Exp Mol Med; 2023 Jul; 55(7):1451-1461. PubMed ID: 37394589
[TBL] [Abstract][Full Text] [Related]
2. Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.
Wu W; Wu M; Peng G; Shi D; Zhang J
Cancer Med; 2019 Dec; 8(18):7523-7531. PubMed ID: 31642210
[TBL] [Abstract][Full Text] [Related]
3. Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior.
Schwartz CJ; Ruiz J; Bean GR; Sirohi D; Joseph NM; Hosfield EM; Jacobs TW; Mukhtar RA; Chen YY; Krings G
Mod Pathol; 2023 May; 36(5):100125. PubMed ID: 36870308
[TBL] [Abstract][Full Text] [Related]
4. Triple Negative Apocrine Carcinomas as a Distinct Subtype of Triple Negative Breast Cancer: A Case-control Study.
Meattini I; Pezzulla D; Saieva C; Bernini M; Orzalesi L; Sanchez LJ; Desideri I; Francolini G; Bonomo P; Greto D; Loi M; Mangoni M; Bruni A; Nori J; Vezzosi V; Bianchi S; Livi L
Clin Breast Cancer; 2018 Oct; 18(5):e773-e780. PubMed ID: 29573977
[TBL] [Abstract][Full Text] [Related]
5. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
[TBL] [Abstract][Full Text] [Related]
6. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
[TBL] [Abstract][Full Text] [Related]
7. Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas.
Sun X; Zuo K; Yao Q; Zhou S; Shui R; Xu X; Bi R; Yu B; Cheng Y; Tu X; Lu H; Yang W
Mod Pathol; 2020 Dec; 33(12):2473-2482. PubMed ID: 32504034
[TBL] [Abstract][Full Text] [Related]
8. Triple-negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple-negative breast cancers.
Arciero CA; Diehl AH; Liu Y; Sun Q; Gillespie T; Li X; Subhedar P
J Surg Oncol; 2020 Nov; 122(6):1232-1239. PubMed ID: 32668059
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
10. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
11. A clinicopathological study of triple-negative breast carcinoma in a patient cohort from a tertiary care center in Sri Lanka.
Wijesinghe HD; Fernando J; Senarath U; Wijesinghe GK; S Lokuhetty MD
Indian J Pathol Microbiol; 2020; 63(3):388-396. PubMed ID: 32769327
[TBL] [Abstract][Full Text] [Related]
12. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences.
Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK
Cells; 2021 Dec; 10(12):. PubMed ID: 34944094
[TBL] [Abstract][Full Text] [Related]
13. Triple-Negative Apocrine Breast Carcinoma Has Better Prognosis despite Poor Response to Neoadjuvant Chemotherapy.
Hu T; Liu Y; Wu J; Hu XL; Zhao G; Liang B; Wang S; Long M
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329934
[TBL] [Abstract][Full Text] [Related]
14. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
15. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes - an observational cohort study in Sweden.
Lindman H; Wiklund F; Andersen KK
BMC Cancer; 2022 Sep; 22(1):1006. PubMed ID: 36138404
[TBL] [Abstract][Full Text] [Related]
17. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers.
Choi J; Jung WH; Koo JS
Histol Histopathol; 2012 Nov; 27(11):1481-93. PubMed ID: 23018247
[TBL] [Abstract][Full Text] [Related]
19. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
[TBL] [Abstract][Full Text] [Related]
20. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
Wang L; Zhai Q; Lu Q; Lee K; Zheng Q; Hong R; Wang S
Ann Med; 2021 Dec; 53(1):1358-1369. PubMed ID: 34396843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
